| Literature DB >> 23300682 |
Hilary D Miller1, Bryan W Clark, David E Hinton, Andrew Whitehead, Stan Martin, Kevin W Kwok, Seth W Kullman.
Abstract
Environmental estrogens are ubiquitous in the environment and can cause detrimental effects on male reproduction. In fish, a multitude of effects from environmental estrogens have been observed including altered courting behavior and fertility, sex reversal, and gonadal histopathology. However, few studies in fish assess the impacts of estrogenic exposure on a physiological endpoint, such as reproduction, as well as the associated morphologic response and underlying global gene expression changes. This study assessed the implications of a 14 day sub-chronic exposure of ethinylestradiol (EE2; 1.0 or 10.0 µg/L EE2) on male medaka fertility, testicular histology and testicular gene expression. The findings demonstrate that a 14 day exposure to EE2 induced impaired male reproductive capacity and time- and dose-dependent alterations in testicular morphology and gene expression. The average fertilization rate/day following the exposure for control, 1.0 and 10.0 µg/L EE2 was 91.3% (±4.4), 62.8% (±8.3) and 28.8% (±5.8), respectively. The testicular morphologic alterations included increased germ cell apoptosis, decreased germinal epithelium and thickening of the interstitium. These changes were highly associated with testicular gene expression changes using a medaka-specific microarray. A pathway analysis of the differentially expressed genes emphasized genes and pathways associated with apoptosis, cell cycle and proliferation, collagen production/extracellular matrix organization, hormone signaling, male reproduction and protein ubiquitination among others. These findings highlight the importance of anchoring global gonadal gene expression changes with morphology and ultimately with tissue/organ function.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23300682 PMCID: PMC3530452 DOI: 10.1371/journal.pone.0052479
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Number of eggs produced per day for medaka breeding groups during the pre- and post-exposure period following a 14 day exposure to EE2 period (mean ± SEM).
No statistical difference was found during the pre-exposure period. One-way ANOVA of the post-exposure time period found significant differences between the control and treatment groups. Different letters indicate statistical difference in the post-exposure time period (p<0.05).
Figure 2Percentage of eggs fertilized for medaka breeding groups during three periods: pre-exposure, male exposure, and post-exposure.
Dashed lines indicate the mean percentage fertilized during the 20-day post-exposure period for each treatment. Different letters indicate a statistical difference (p<0.05).
Figure 3Sections of testis from 6 month old male medaka stained with H&E.
A: Transverse section of testis showing both lobes joined by the central efferent duct. Spermatogonial germ cells are at periphery of the organ. B: A longitudinal section of a DMSO control animal showing normal testicular morphology. Dark basophilic staining central region is comprised of spermatozoa filling lumen of efferent duct. As in A (above) spermatogonial cells are restricted to the periphery of the organ. Between the periphery and the CED various stages of spermatogenesis are encountered. C: Animal exposed to 1.0 µg/L EE2 for 7 days. When interstitium of animals from this group were compared to controls only one animal showed enhanced thickening of the interstitium and this was limited in extent. D: Animal exposed to 10.0 µg/L EE2 for 7 days. Thickened interstitium was apparent in a zone half way between the periphery and the CED. E: Animal exposed to 1.0 µg/L EE2 for 14 days. At this time, moderate thickening of the interstitium and increased area of clear space devoid of germ cells characterized the lobular lumen. There is a decrease in the proportion of intermediate staged germ cells as evident by the smaller area occupied by these cells (i.e. spermatocytes and spermatids) and a general decrease in germinal epithelium. F: Animal exposed to 10.0 µg/L EE2 for 14 days has a severe thickening of the interstitium, increased vacuolization, and an overall decrease in germinal epithelium. G: Animal exposed to 1.0 µg/L EE2 for 14 days followed by 14 days of recovery showed return toward control morphology. The thickening of the interstitium has diminished compared to E or F and there is an abundance of intermediate stage germ cells indicating active spermatogenesis. The CED does not have many spermatozoa but there are spermatids and spermatozoa in the efferent duct system preparing to enter the central duct. H: Animal exposed to 10.0 µg/L EE2 for 14 days followed by 14 days of recovery. There is continued thickening of the interstitium and significantly altered spermatogenesis. Only mature sperm and a few spermatogonia are present but intermediate stages of germ cells are absent or greatly reduced indicating little active spermatogenesis. There is also eosinophilic change in the interstitium.
Figure 4Testis of medaka following a 14 day EE2 exposure followed by active breeding with 3 females for 20 days.
A: DMSO control male. B: Male exposed to 1.0 µg/L EE2. There is thickening of the interstitium, an increase in proportion of spermatocytes, minimal spermatozoa. C: Male exposed to 1.0 µg/L EE2. This organ has severe thickening of the interstitium with a focal area of basophilic cells center of field and a severe decrease in germinal epithelium. D: Male exposed to 10.0 µg/L EE2. Severe thickening of interstitium and severe loss of germinal epithelium are. There are, however, spermatocytes and spermatids present suggesting active spermatogenesis. E: Male exposed to 10.0 µg/L EE2. There is severe thickening of the interstitium with loss of germinal epithelium.
Figure 5Principle components analysis based on significant genes from 1.0 µg/L EE2 treatment group (circles) and 10.0 µg/L EE2 treatment group (diamond) on day 1 (purple), day 7 (blue), and day 14 (green).
The first principal component accounted for 47.7% of the data variability and was largely influenced by the strong temporal response in each EE2 treatment. The second (16.3%) and third (13.8%) principal components appeared to be influenced by dose accounting for a combined 77.8% of the total data variability.
Figure 6Hierarchical cluster diagram of significantly different genes following exposure to EE2 in males.
A temporal trend is clearly observed. The same day sampling points cluster together with day 14 being the most distinct from day 1 and 7.
Figure 7Venn diagrams of significantly different genes on day 1, day 7 and day 14 of EE2 exposure for a) the 1.0 µg/L EE2 treatment group and b) the 10.0 µg/L EE2 treatment group.
The 54 common genes in the 1.0 µg/L EE2 treatment group, the 92 common genes in the 10.0 µg/L EE2 treatment group, the 2141 genes unique to day 14 1.0 µg/L EE2 treatment group, and the 4546 unique genes to day 14 10.0 µg/L EE2 treatment group, highlighted by the yellow box, were used for Ingenuity Pathway Analysis.
Significant genes common to all sampling points and treatments.
| Significant Genes Common ToAll Treatments: | ACTA1, ACTG1, ADAMTS20, BMP6, CALD1, CD81, CDH5,COL4A1, COL4A2, CXXC5, CYP19A1, EFEMP2, EPB41, FAM187A, FAM20C, FLNC, FOLR1, GPC1, ID1, KCNS2, MYOCD, NR0B1, NR0B2, NR3C3, NR5A1, PDLIM3, PGM5, PTPRN, SLPI, SOX9, TGM2, TULP1, VENTX, UNKNOWN (ENSORLG00000006007, ENSORLG00000009404) |
IPA top associated molecular networks function generated from gene lists comprised of significant genes common to all sampling days in each treatment.
| Significant Gene List | Top Associated Molecular Network Functions | Network Genes and Molecules | Ontology of Genes and Molecules Common to 1.0 and 10.0 IPA Networks |
| 1.0 µg/L EE2 common to all sampling days | 1. Embryonic Development, Organismal Development, Organ Development (Score = 46) |
|
|
| 2. Connective TissueDisorders, Genetic Disorder, Dermatological Diseasesand Conditions(Score = 23) | BRS3, CAV1, |
| |
| 3. Lipid Metabolism, Liver Cholestasis, Molecular Transport (Score = 16) |
|
| |
| 10.0 µg/L EE2 common to all sampling days | 1. Cancer, ReproductiveSystem Disease,Drug Metabolism(Score = 64) |
|
|
| 2. Cell Cycle, Cellular Development, Hematological System Development and Function (Score = 30) | 2810007J24RIK, beta-estradiol, CCND1, | ||
| 3. Embryonic Development, Tissue Morphology, Cardiovascular System Development and Function (Score = 27) | ADCY, Akt, Alp, Ap1, |
Significantly different genes listed in bold.
IPA top associated molecular networks function generated from gene lists comprised of significant genes unique to day 14 in each treatment. Significantly different genes listed in bold.
| Significant Gene List | Top Associated Network Functions | Network Genes and Molecules | Ontology of Genes and Molecules Common to 1.0 and 10.0 IPA Networks |
| 1.0 µg/L EE2 genes unique to Day 14 | 1. Post-Translational Modification, Protein Degradation, ProteinSynthesis (Score = 40) |
|
|
| 2. Lipid Metabolism, Nucleic Acid Metabolism, Small Molecule Biochemistry (Score = 37) |
|
| |
| 3. Post-Translational Modification, GeneExpression, MetabolicDisease (Score = 35) |
| ||
| 4. Developmental Disorder, Genetic Disorder,Neurological Disease(Score = 33) |
| ||
| 5. Protein Degradation,Protein Synthesis,Embryonic Development(Score = 33) |
| ||
| 10.0 µg/L EE2 genes unique to Day 14 | 1. Cell Cycle, ConnectiveTissue Developmentand Function, CarbohydrateMetabolism (Score = 34) |
| |
| 2. Cell Signaling, Nutritional Disease, Psychological Disorders (Score = 31) |
| ||
| 3. Cellular Assembly and Organization, DNA Replication, Recombination, & Repair, RNA Post-Transcriptional Modification (Score = 31) |
| ||
| 4. Cell Cycle, CellularAssembly and Organization,DNA Replication,Recombination, &Repair (Score = 31) |
| ||
| 5. Post-Translational Modification, LipidMetabolism, Nucleic AcidMetabolism(Score = 29) |
|
IPA top canonical pathways generated from gene lists comprised of significant genes unique to day 14 in each treatment.
| Significant Gene List | Top Canonical Pathways | Pathway Genes |
| 1.0 µg/L EE2 genes uniqueto Day 14 | 1. Leukocyte Extravasation Signaling (ratio = 34/199; pval = 2.7E-050) |
|
| 2. VDR/RXR Activation (ratio = 18/81; pval = 6.1E-05) |
| |
| 3. Production of Nitric Oxide & Reactive Oxygen Species in Macrophages (ratio = 28/189;pval = 1.8E-04) |
| |
| 4. RAR Activation (ratio = 29/183; pval = 1.9E-04) |
| |
| 5. Reelin Signaling in Neurons (ratio = 17/82;pval = 2E-04) |
| |
| 10.0 µg/L EE2 genes uniqueto Day 14 | 1. Regulation of eIF4 & p70S6K Signaling (ratio = 35/135; pval = 1.6E-05) |
|
| 2. ERK/MAPK Signaling (ratio-55/204; pval = 3.5E-05) |
| |
| 3. Protein Ubiquitination Pathway (ratio = 72/204; pval = 3.9E-05) |
| |
| 4. EIF2 Signaling (ratio = 31/104; pval = 5.3E-05) |
| |
| 5. Production of Nitric Oxide & Reactive Oxygen Species in Macrophages(ratio = 47/189;pval = 2.15E-04) |
|
Only significant genes found in the pathway are listed.
Figure 8Top ranked IPA Molecular Network generated from differentially expressed genes unique to day 14 in the 10.0 µg/L EE2 treatment.
Myc family of genes is central to this Molecular Network suggesting an important role in the observed changes in gene expression and histology on day 14 in the 10.0 µg/L treatment group.
Figure 9Second top ranked IPA Molecular Network generated from differentially expressed genes unique to day 14 in the 10.0 µg/L EE2 treatment.
G-protein coupled receptors (GPCRs) are emphasized in this Molecular Network indicating a significant effect on G-protein signaling pathways including the G-protein estrogen receptor (GPER) on day 14 in the 10.0 µg/L treatment group.